Spyre Therapeutics (SYRE) Receivables - Accured (2019 - 2025)
Historic Receivables - Accured for Spyre Therapeutics (SYRE) over the last 7 years, with Q3 2025 value amounting to $3.6 million.
- Spyre Therapeutics' Receivables - Accured rose 11176.47% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 11176.47%. This contributed to the annual value of $3.4 million for FY2024, which is 27777.78% up from last year.
- Per Spyre Therapeutics' latest filing, its Receivables - Accured stood at $3.6 million for Q3 2025, which was up 11176.47% from $3.5 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Receivables - Accured ranged from a high of $3.6 million in Q3 2025 and a low of $100000.0 during Q3 2021
- Its 5-year average for Receivables - Accured is $1.3 million, with a median of $650000.0 in 2023.
- Per our database at Business Quant, Spyre Therapeutics' Receivables - Accured plummeted by 5000.0% in 2021 and then surged by 170000.0% in 2024.
- Spyre Therapeutics' Receivables - Accured (Quarter) stood at $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022, then soared by 800.0% to $900000.0 in 2023, then surged by 277.78% to $3.4 million in 2024, then increased by 5.88% to $3.6 million in 2025.
- Its last three reported values are $3.6 million in Q3 2025, $3.5 million for Q2 2025, and $3.4 million during Q1 2025.